Patent US4338413A successfully refreshed from Google Patents.
Patent US5160727A successfully refreshed from Google Patents.
US5160727A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tumor cell sensitization method using quinazolinedione derivatives
Assignee: Hadassah Medical Organization
•
Filing: 1990-03-21
•
Granted: 1992-11-03
•
Expires: 2010-03-21
Abstract
Abstract A method for sensitizing cancer cells which have become resistant to treatment with one or more anticancer agents which comprises treating said cells with a quinazolinedione compound.
Inventors
- 👤 Wayne Klohs
- 👤 Avner Ramu
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 10:29
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61P; A61P35/00
Claims Analysis
Total Claims: 3
Claim 1
Independent Claim
174 words
A method of treating a patient having cancer cells which are resistance to multiple drugs which comprises administering to said patient an anticancer agent selected from the group consisting of vinblastine, vincristine, doxorubicin, daunorubicin, trimetrexate, piritrexim, etoposide, 7,10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-(methylamino)ethyl]amino]anthra[1,9-cd]pyrazol-6-(2H)-one dihydrochloride, 5-[(2-aminoethyl)amino]-2-[2-(diethylamino)ethyl]-2H-[1]benzothiopyrano[4,3,2-cd]indazol-8-ol trihydrochloride, and taxol and an amount of a compound of the following formula which is capable of rendering the resistant cells sensitive to anticancer agents: wherein X is an alkylene chain having from three to seven carbon atoms; each of R 1 and R 2 is hydrogen, chlorine, fluorine, bromine, or lower alkoxy having from one to four carbon atoms and which is straight or branched; R 3 is hydrogen or a straight or branched lower alkyl of from one to three carbon atoms; each of R 4 and R 5 is hydrogen, chlorine, fluorine, bromine, or lower alkylthio having from one to four carbon atoms and which is straight or branched with the proviso that one of R 4 and R 5 is other than hydrogen; or a pharmaceutically acceptable acid-addition salt thereof.
Claim 2
Independent Claim
174 words
A method of treating a patient having cancer cells which are resistance to multiple drugs which comprises administering to said patient an anticancer agent selected from the group consisting of vinblastine, vincristine, doxorubicin, daunorubicin, trimetrexate, piritrexim, etoposide, 7,10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-(methylamino)ethyl]amino]anthra[1,9-cd]pyrazol-6-(2H)-one dihydrochloride, 5-[(2-aminoethyl)amino]-2-[2-(diethylamino)ethyl]-2H-[1]benzothiopyrano[4,3,2-cd]indazol-8-ol trihydrochloride, and taxol and an amount of a compound of the following formula which is capable of rendering the resistant cells sensitive to anticancer agents: wherein X is an alkylene chain having from three to seven carbon atoms; each of R 1 and R 2 is hydrogen, chlorine, fluorine, bromine, or lower alkoxy having from one to four carbon atoms and which is straight or branched; R 3 is hydrogen or a straight or branched lower alkyl of from one to three carbon atoms; each of R 4 and R 5 is hydrogen, chlorine, fluorine, bromine, or lower alkylthio having from one to four carbon atoms and which is straight or branched with the proviso that one of R 4 and R 5 is other than hydrogen; or a pharmaceutically acceptable acid-addition salt thereof.
Claim 3
Dependent Claim
10 words
The method of claim 1 wherein the compound is tioperidone.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-11-03 | 1996-05-04 | 1996-11-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-11-03 | 2000-05-04 | 2000-11-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-11-03 | 2004-05-04 | 2004-11-03 | $7700.00 | Window Closed / Lapsed |